216 related articles for article (PubMed ID: 28572054)
1. Targeting the programmed cell death-1 pathway in rheumatoid arthritis.
Sandigursky S; Silverman GJ; Mor A
Autoimmun Rev; 2017 Aug; 16(8):767-773. PubMed ID: 28572054
[TBL] [Abstract][Full Text] [Related]
2. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
3. B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives.
Nakken B; Munthe LA; Konttinen YT; Sandberg AK; Szekanecz Z; Alex P; Szodoray P
Autoimmun Rev; 2011 Nov; 11(1):28-34. PubMed ID: 21777703
[TBL] [Abstract][Full Text] [Related]
4. Different lymphocyte populations in rheumatoid arthritis and their relationship to anti-Ig activities.
Natvig JB; Froland SS; Wisloff F; Munthe E
Ann Clin Res; 1975 Jun; 7(3):146-53. PubMed ID: 1081361
[TBL] [Abstract][Full Text] [Related]
5. Targeting lymphocyte co-stimulation: from bench to bedside.
Felix NJ; Suri A; Salter-Cid L; Nadler SG; Gujrathi S; Corbo M; Aranda R
Autoimmunity; 2010 Nov; 43(7):514-25. PubMed ID: 20429850
[TBL] [Abstract][Full Text] [Related]
6. T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE
Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
[TBL] [Abstract][Full Text] [Related]
7. Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?
Caporali R; Bugatti S; Cavagna L; Antivalle M; Sarzi-Puttini P
Autoimmun Rev; 2014 Jan; 13(1):49-53. PubMed ID: 23777823
[TBL] [Abstract][Full Text] [Related]
8. T-lymphocyte subpopulations in rheumatoid arthritis.
Pfreundschuh M; Gause A; Dörken B; Gram N; Rehn C; Beck J
Z Rheumatol; 1980; 39(9-10):348-55. PubMed ID: 6969958
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 blockade in the treatment of rheumatoid arthritis: an update.
Cutolo M; Sulli A; Paolino S; Pizzorni C
Expert Rev Clin Immunol; 2016; 12(4):417-25. PubMed ID: 26679631
[TBL] [Abstract][Full Text] [Related]
10. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
11. The PD-1/PD-Ls pathway and autoimmune diseases.
Dai S; Jia R; Zhang X; Fang Q; Huang L
Cell Immunol; 2014 Jul; 290(1):72-9. PubMed ID: 24908630
[TBL] [Abstract][Full Text] [Related]
12. The CD27-CD70 pathway and pathogenesis of autoimmune disease.
Han BK; Olsen NJ; Bottaro A
Semin Arthritis Rheum; 2016 Feb; 45(4):496-501. PubMed ID: 26359318
[TBL] [Abstract][Full Text] [Related]
13. Role of immune system, apoptosis and angiogenesis in pathogenesis of rheumatoid arthritis and joint destruction, a systematic review.
Dhaouadi T; Sfar I; Abelmoula L; Jendoubi-Ayed S; Aouadi H; Ben Abdellah T; Ayed K; Zouari R; Gorgi Y
Tunis Med; 2007 Dec; 85(12):991-8. PubMed ID: 19170375
[TBL] [Abstract][Full Text] [Related]
14. [Indications and efficacy of biologics in inflammatory arthritis].
Combe B
Bull Acad Natl Med; 2012 Oct; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
[TBL] [Abstract][Full Text] [Related]
15. [T and B lymphocyte subpopulations with HLA-DR surface molecules in rheumatoid arthritis, using a monoclonal lymphocytotoxic antibody. Poorly and highly developed rheumatoid arthritis].
Mercier P; Dallest R; Olmeta C; Gaborit P; Gatti P; Roux H
Rev Rhum Mal Osteoartic; 1981 Nov; 48(11):713-9. PubMed ID: 6975966
[TBL] [Abstract][Full Text] [Related]
16. [Pathological mechanisms in rheumatoid arthritis].
Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1147-52. PubMed ID: 23961659
[TBL] [Abstract][Full Text] [Related]
17. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.
Raptopoulou AP; Bertsias G; Makrygiannakis D; Verginis P; Kritikos I; Tzardi M; Klareskog L; Catrina AI; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2010 Jul; 62(7):1870-80. PubMed ID: 20506224
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
Manadan AM; Block JA
Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
[TBL] [Abstract][Full Text] [Related]
19. What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials.
Smolen JS
J Rheumatol Suppl; 2007 Jul; 79():15-20. PubMed ID: 17611974
[TBL] [Abstract][Full Text] [Related]
20. B lymphocyte function in patients with rheumatoid arthritis: impact of regulatory T lymphocytes and macrophages--modulation by antirheumatic drugs.
Petersen J
Dan Med Bull; 1988 Apr; 35(2):140-57. PubMed ID: 3282810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
